GlassScriptPhysician profile
Danielle L Toal
NPI 1346781069
$14,771.53
in general payments reported to CMS, 2019-2025
30 companies · $3,034 in 2025
The $3,034 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,467 · 2022: $2,916 · 2023: $3,124 · 2024: $3,230 · 2025: $3,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,001 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,001.33 |
| Education | $386.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,988.65 | 2021-2025 | |
| Janssen Biotech, INC. | $1,553.76 | 2021-2025 | Tremfya, Remicade, Stelara |
| Regeneron Healthcare Solutions, INC. | $1,479.32 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,203.42 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,114.22 | 2021-2025 | |
| Leo Pharma INC. | $924.20 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $781.53 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $752.94 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $670.21 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $509.97 | 2021-2025 | Blu-U, Odomzo |
| Dermavant Sciences, INC. | $399.37 | 2022-2024 | Vtama |
| Genzyme Corporation | $378.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $347.45 | 2021-2022 | |
| Pfizer INC. | $287.40 | 2022-2024 | |
| Galderma Laboratories, L.P. | $247.17 | 2021-2025 | Nemluvio, Oracea, Epsolay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $210.68 | 2021-2024 | Opzelura |
| Strata Skin Sciences, INC. | $153.41 | 2023 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.59 | 2021 | |
| Arcutis Biotherapeutics, INC. | $97.34 | 2023-2025 | Zoryve |
| Botanix Sb INC | $89.75 | 2025 | Sofdra |
| Almirall LLC | $86.53 | 2021-2025 | Seysara, Klisyri |
| Convatec INC. | $78.54 | 2024-2025 | |
| Genentech USA, INC. | $74.10 | 2022-2025 | Xolair |
| Organon LLC | $57.54 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $38.99 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $33.43 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.15 | 2023 | Spevigo |
| Biofrontera INC. | $22.85 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Kyowa Kirin, INC. | $17.62 | 2022 | |
| Smith+Nephew, INC. | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Toal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.